BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,230,770 | +0.6% | 3,846,154 | 0.0% | 26.28% | -5.5% |
| Q2 2023 | $27,076,924 | -15.6% | 3,846,154 | 0.0% | 27.82% | -37.4% |
| Q1 2023 | $32,076,924 | -27.4% | 3,846,154 | 0.0% | 44.43% | -14.5% |
| Q4 2022 | $44,153,847 | -8.9% | 3,846,154 | 0.0% | 52.00% | +132.2% |
| Q3 2022 | $48,462,000 | +19.1% | 3,846,154 | 0.0% | 22.39% | +39.3% |
| Q2 2022 | $40,692,000 | -34.9% | 3,846,154 | 0.0% | 16.07% | -36.8% |
| Q1 2022 | $62,538,000 | +45.4% | 3,846,154 | 0.0% | 25.44% | +41.3% |
| Q4 2021 | $43,000,000 | – | 3,846,154 | – | 18.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |